Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals, Inc.

This place is about more than a pharmaceutical career. It’s about making a real difference in the lives of patients. That’s why we’re here. That’s why you should maybe think about being here, too.Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	589K -	2.04M 247.20%	2.43M 18.73%	1.19M 50.86%	71K 94.05%	1.08M 1,418.31%	4.74M 339.42%	4.01M 15.28%
cost of revenue								1.10M -
gross profit	589K -	2.04M 247.20%	2.43M 18.73%	1.19M 50.86%	71K 94.05%	1.08M 1,418.31%	4.74M 339.42%	2.92M 38.46%
selling and marketing expenses
general and administrative expenses	1.53M -	1.94M 26.48%	6.66M 243.42%	13.52M 103.02%	18.03M 33.34%	24.52M 36.05%	42.39M 72.86%	58.09M 37.03%
selling general and administrative expenses	1.53M -	1.94M 26.48%	6.66M 243.42%	13.52M 103.02%	18.03M 33.34%	24.52M 36.05%	42.39M 72.86%	58.09M 37.03%
research and development expenses	5.10M -	9.23M 81.04%	24.48M 165.13%	41.51M 69.56%	57.00M 37.32%	84.25M 47.82%	130.22M 54.56%	167.43M 28.57%
other expenses	-1K -	-48K 4,700%	1.59M 3,422.92%	-1.19M 174.80%	-71K 94.05%	61K 185.92%	4.97M 8,054.10%	-159K 103.20%
cost and expenses	6.04M -	9.13M 51.01%	28.71M 214.56%	53.83M 87.50%	74.95M 39.24%	108.78M 45.13%	172.62M 58.69%	226.62M 31.28%
operating expenses	6.04M -	9.13M 51.01%	28.71M 214.56%	53.83M 87.50%	74.95M 39.24%	108.78M 45.13%	172.62M 58.69%	225.52M 30.65%
interest expense	11K -	8K 27.27%					4.32M -
ebitda	-5.92M -	-9.02M 52.48%	-28.71M 218.26%	-53.83M 87.50%	-74.95M 39.24%	-107.70M 43.69%	-167.88M 55.88%	-221.51M 31.94%
operating income	-6.04M -	-9.13M 51.01%	-28.71M 214.56%	-53.83M 87.50%	-74.95M 39.24%	-107.70M 43.69%	-167.88M 55.88%	-222.61M 32.60%
depreciation and amortization	92K -	128K 39.13%	471K 267.97%	887K 88.32%	948K 6.88%	922K 2.74%	983K 6.62%	1.10M 11.70%
total other income expenses net	-1K -	-48K 4,700%	1.59M 3,422.92%	3.41M 113.79%	1.14M 66.54%	61K 94.65%	3.96M 6,398.36%	8.08M 103.81%
income before tax	-6.02M -	-9.16M 52.13%	-27.11M 196.11%	-50.42M 85.96%	-73.81M 46.39%	-107.64M 45.83%	-163.92M 52.28%	-214.53M 30.88%
income tax expense	10K -	-40K 500%	1.59M 4,087.50%	-887K 155.61%	-948K 6.88%	-922K 2.74%	-3.96M 329.93%
net income	-6.02M -	-9.16M 52.13%	-27.11M 196.11%	-49.53M 82.68%	-72.86M 47.10%	-106.72M 46.46%	-159.95M 49.88%	-214.53M 34.12%
weighted average shs out	13.88M -	13.88M 0%	12.14M 12.51%	24.18M 99.10%	30.45M 25.95%	38.44M 26.23%	51.98M 35.24%	58.07M 11.71%
weighted average shs out dil	13.88M -	13.88M 0%	12.14M 12.51%	24.18M 99.10%	30.45M 25.95%	38.44M 26.23%	51.98M 35.24%	58.07M 11.71%
eps	-0.43 -	-0.66 53.49%	-2.23 237.88%	-2.05 8.07%	-2.39 16.59%	-2.78 16.32%	-3.08 10.79%	-3.69 19.81%
epsdiluted	-0.43 -	-0.66 53.49%	-2.23 237.88%	-2.05 8.07%	-2.39 16.59%	-2.78 16.32%	-3.08 10.79%	-3.69 19.81%

COM:CRINETICS

Crinetics Pharmaceuticals

Last Close

57.03

22/11 21:00

Market Cap

4.01B

Beta: -

Volume Today

1.02M

Avg: -

Preview